It enhances TMZ cytotoxicity in MGMT-positive but not in MGMT-negative glioblastomas in vitro, but the required concentration (20 mM) is very high (Montaldi and Sakamoto-Hojo, 2013), and clinical studies were unsuccessful (Malfatti et al., 2023). The gene discussed is MGMT; the disease is glioblastoma.